PHVS - Pharvaris N.V.

QQQ $ 452.83 $ 6.97 (1.56 %)

DIA $ 399.31 $ 3.70 (0.94 %)

SPY $ 529.09 $ 6.48 (1.24 %)

TLT $ 92.14 $ 1.24 (1.36 %)

GLD $ 220.89 $ 2.80 (1.28 %)

Previous Close

$ 22.1

Open

$ 21.07

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 21.07 - $ 22.97

52 Week Range

$ 8.20 - $ 33.00

Volume

60,954

Average Volume

Market Cap

1.16B

Beta (5Y Monthly)

$ -1.16

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wedbush Maintains Outperform on Pharvaris,...
05/09/2024 12:56:01

Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers the price target from $35 to $31.

Pharvaris Q1 2024 Adj EPS €(0.52) Beats €(...
05/08/2024 22:10:20

Morgan Stanley Maintains Overweight on Pha...
04/22/2024 17:28:14

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and maintains $34 price target.

Morgan Stanley Maintains Overweight on Pha...
04/15/2024 16:45:15

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and lowers the price target from...

Pharvaris NV Files For Mixed Shelf Offerin...
04/12/2024 20:21:19

- SEC Filing

JMP Securities Maintains Market Outperform...
04/11/2024 16:13:13

JMP Securities analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price tar...

Wedbush Reiterates Outperform on Pharvaris...
04/11/2024 13:59:26

Wedbush analyst Laura Chico reiterates Pharvaris (NASDAQ:PHVS) with a Outperform and maintains $35 price target.

Pharvaris Q4 EPS $(0.80) Misses $(0.58) Es...
04/10/2024 21:32:57

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.58) b...

Pharvaris N.V. Q4 2023 EPS €(0.74) Vs €(1....
04/10/2024 20:14:54

Fourth Quarter and Full Year 2023 Financial Results

Pharvaris Appoints David Nassif As CFO
04/10/2024 20:09:25

Wedbush Reiterates Outperform on Pharvaris...
03/19/2024 13:07:45

Wedbush analyst Laura Chico reiterates Pharvaris (NASDAQ:PHVS) with a Outperform and maintains $35 price target.

Pharvaris Announces Phase 3 Clinical Study...
03/18/2024 10:51:59

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to t...

Pharvaris Files For Resale Of Up To 5.55M...
03/06/2024 21:48:50

Pharvaris Stated That Positive Results Fro...
02/22/2024 11:54:52

JMP Securities Reiterates Market Outperfor...
02/14/2024 18:24:35

JMP Securities analyst Jonathan Wolleben reiterates Pharvaris (NASDAQ:PHVS) with a Market Outperform and maintains $49 price...

JMP Securities Maintains Market Outperform...
01/23/2024 13:42:54

JMP Securities analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price tar...

fda-clears-pharvaris-trial-for-investigational-drug-for-swollen-blood-vessels-stock-jumps

FDA Clears Pharvaris' Trial For Investigat...
01/22/2024 17:28:14

Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn ab...

The FDA Has Lifted The Clinical Hold On Ph...
01/22/2024 11:52:28

Pharvaris Provides Business Update, Outlin...
01/05/2024 11:54:33

B of A Securities Maintains Underperform o...
12/07/2023 21:07:54

B of A Securities analyst Tazeen Ahmad maintains Pharvaris (NASDAQ:PHVS) with a Underperform and raises the price target fro...